Gerrard Schmid
CIK 1732384 · View on SEC EDGAR ↗
First SEC filing: Feb. 8, 2022 · Latest: Feb. 8, 2022
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 16, 2021 | DBD | S | 9,412 | $17.11 | $161,039 | 564,336 Direct | -1.64% | Disposed | 297.9% (price as of 2026-08-21) |
| March 16, 2021 | DBD | S | 53,636 | $16.39 | $879,094 | 573,748 Direct | -8.55% | Disposed | 315.4% (price as of 2026-08-21) |
| March 16, 2021 | DBD | S | 9,412 | $17.11 | $161,039 | 564,336 Direct | -1.64% | Disposed | 297.9% (price as of 2026-08-21) |
| March 16, 2021 | DBD | S | 53,636 | $16.39 | $879,094 | 573,748 Direct | -8.55% | Disposed | 315.4% (price as of 2026-08-21) |
| March 15, 2021 | DBD | S | 39,449 | $17.15 | $676,550 | 627,384 Direct | -5.92% | Disposed | 297.0% (price as of 2026-08-21) |
| March 15, 2021 | DBD | S | 39,449 | $17.15 | $676,550 | 627,384 Direct | -5.92% | Disposed | 297.0% (price as of 2026-08-21) |
| March 6, 2020 | DBD | P | 10,000 | $5.69 | $56,900 | 578,856 Direct | +1.76% | Acquired | 1096.5% (price as of 2026-08-21) |
| Oct. 31, 2019 | DBD | P | 28,000 | $6.94 | $194,320 | 518,070 Direct | +5.71% | Acquired | 881.0% (price as of 2026-08-21) |
| March 4, 2019 | DBD | P | 22,222 | $8.80 | $195,554 | 490,070 Direct | +4.75% | Acquired | 673.6% (price as of 2026-08-21) |
| May 8, 2018 | DBD | P | 10,000 | $11.85 | $118,500 | 10,000 Indirect | — | Acquired | 474.5% (price as of 2026-08-21) |
| May 4, 2018 | DBD | P | 8,300 | $11.80 | $97,940 | 117,245 Direct | +7.62% | Acquired | 476.9% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 30, 2020 | DBD | Non-Qualified Stock Option [F4] | Common Shares (253,907) | — | Jan. 30, 2030 | 253,907 | Acquired |
| Jan. 30, 2020 | DBD | Non-Qualified Stock Option [F4] | Common Shares (253,907) | $11.96 | Jan. 30, 2030 | 253,907 | Acquired |
| April 25, 2019 | DBD | Performance Share Units | Common Shares (56,059) | — | April 25, 2022 | 56,059 | Acquired |
| April 25, 2019 | DBD | Non-Qualified Stock Option [F3] | Common Shares (34,678) | $13.98 | April 25, 2029 | 34,678 | Acquired |
| Jan. 29, 2019 | DBD | Non-Qualified Stock Option [F4] | Common Shares (676,814) | $4.49 | Jan. 29, 2029 | 676,814 | Acquired |
| Feb. 21, 2018 | DBD | Non-Qualified Stock Option [F3] | Common Shares (192,049) | $15.35 | Feb. 20, 2028 | 192,049 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
DBD
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | — | — | — | $4,072,158 | $4,291,389 |
| 2021 | — | — | — | — | $3,063,679 | — | $51,643 | $26,169,529 |
| 2020 | — | — | — | — | $1,133,160 | — | $55,637 | $5,312,150 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.